The approval seems to have come at the right time for GSK, with sales of the Advair respiratory drug falling 7% in June alone. Generic versions of Advair are expected by early next years, further eating into sales.
Benlysta’s approval in Europe, following earlier US approval, means it should balance out profit from the Advair losses, meaning that GSK are expected to maintain large profits next year, just as other big pharmaceutical companies struggle.
Looking for a job in the pharmaceutical industry? Start by clicking here, now